

## **IN THE CLAIMS**

1-54 (Canceled)

55. (New) An adenovirus vector comprising an adenovirus early gene essential for propagation under the control of a human prostate specific antigen promoter and a human prostate specific antigen enhancer.

56. (New) The adenovirus vector of Claim 55, further comprising a transgene.

57. (New) The adenovirus vector of Claim 56, wherein the transgene is a therapeutic gene.

58. (New) The adenovirus vector of Claim 55, wherein the adenovirus early gene is selected from the group consisting of E1A, E1B, and E4.

59. (New) The adenovirus vector of Claim 55, wherein the adenovirus is derived from serotype 5.

60. (New) A method for treating a patient suffering from prostate cancer, comprising:  
introducing into said patient an adenovirus vector comprising an adenovirus early gene essential for propagation under the control of a human prostate specific antigen promoter and a human prostate specific antigen enhancer.